KARACHI: Pakistan Pharmaceutical Manufacturers’ Association (PPMA) has called upon the interim federal government to immediately allow as per the law, a reasonable increase in prices of 262 medicines, whose applications have been pending for over one-and-half years, as any further delay by the authorities concerned in deciding these cases means more essential drugs wouldn’t be available in the local market.
The demand to this effect was made by PPMA Central Chairman, Mian Khalid Misbah-ur-Rehman while speaking at a press conference. He was accompanied by two former PPMA chairmen, Zahid Saeed, and Kaiser Waheed, and other office-bearers of the association.
PPMA Chairman informed journalists that revision in prices of these medicines had become highly essential as the last time such an increase had been allowed by the government the value of the dollar was less than Rs 200. “In addition to the phenomenal increase in the dollar exchange rate, the production cost of medicines has increased manifold due to record inflation,” he said.
He warned that more multinational drug producers would be left with no option but to wind up their businesses if the government unnecessarily kept on delaying the decision to allow an increase in the prices of medicines whose hardship cases had been pending with the authorities for long.
“The number of multinational pharmaceutical companies in Pakistan has already significantly decreased over the past many years as any further reduction in their number will go against the current efforts of the government to attract foreign investment to Pakistan,” he said.
Rehman told media persons that over 100 essential drugs were already unavailable in the market as any further increase in the number of missing medicines would be a serious disservice to the patients in the country.
He said that the sustainability of the Pakistani pharmaceutical industry, which had been meeting up to 95 per cent demand for medicines in the country, would be seriously threatened if the government didn’t review its drug pricing system.
He said the pricing system should effectively work in the case of the local pharmaceutical industry as up to 95 per cent of raw materials of the medicines were imported whose prices increase with the devaluation of the rupee.
[embedpost slug=”pakistani-it-firms-win-eight-awards-at-apicta-in-hong-kong”]
